Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 21-year-old man with type 1 diabetes mellitus is managed in the intensive care unit for diabetic ketoacidosis. Over the past 14 hours, he has received aggressive intravenous fluid resuscitation and a continuous intravenous regular insulin infusion. His fingerstick blood glucose is now 160 mg/dL160 \text{ mg/dL}. He is awake, alert, and requesting food. Arrange the following steps in the most appropriate chronological sequence to safely transition this patient's treatment and de-escalate therapy.

  1. 1Evaluate the basic metabolic panel to confirm the anion gap has closed to 12 mEq/L12 \text{ mEq/L} or less.
  2. 2Administer the first scheduled dose of subcutaneous basal insulin.
  3. 3Maintain the continuous intravenous regular insulin infusion for an overlap period of 1 to 2 hours.
  4. 4Discontinue the continuous intravenous regular insulin infusion.

Cevap

The correct sequence requires first confirming the resolution of ketoacidosis (closed anion gap), followed by the administration of subcutaneous basal insulin, overlapping the intravenous and subcutaneous insulin for 1 to 2 hours, and finally discontinuing the intravenous infusion.
The successful management and evaluation of a patient recovering from diabetic ketoacidosis (DKA) relies heavily on appropriate treatment de-escalation protocols. First, the physician must confirm DKA resolution (anion gap ≤12 mEq/L\le 12 \text{ mEq/L}, blood pH>7.3pH > 7.3, and bicarbonate ≥15 mEq/L\ge 15 \text{ mEq/L}). Once confirmed and the patient is able to eat, subcutaneous basal insulin is administered. Crucially, intravenous regular insulin has a half-life of roughly 5 to 9 minutes, whereas subcutaneous insulin has a delayed onset of 1 to 2 hours. Therefore, the intravenous infusion must be maintained for a 1- to 2-hour overlap period to prevent a critical window of absolute insulin deficiency. Only after this overlap can the intravenous infusion be safely discontinued.

Adım Adım Çözüm

1
Confirm clinical and biochemical resolution of diabetic ketoacidosis.
Verification of an anion gap ≤12 mEq/L\le 12 \text{ mEq/L} and the patient's ability to tolerate oral intake.
Intravenous therapy should not be de-escalated until the underlying acid-base derangement is fundamentally resolved.
2
Administer subcutaneous basal insulin.
A depot of long-acting insulin is placed in the subcutaneous tissue.
To provide necessary baseline glycemic control as the patient transitions away from continuous infusions.
3
Overlap intravenous and subcutaneous insulin.
The intravenous regular insulin infusion is maintained for 1 to 2 hours.
Subcutaneous insulin requires 1 to 2 hours to be absorbed and reach systemic circulation. Overlapping prevents a critical gap in insulin coverage.
4
Discontinue intravenous insulin.
The continuous intravenous regular insulin infusion is stopped.
The subcutaneous insulin has now reached steady systemic levels, allowing safe cessation of the infusion without risk of rebound ketoacidosis.

Anahtar Kavram

When transitioning a patient from intravenous to subcutaneous insulin following diabetic ketoacidosis, a 1- to 2-hour overlap is mandatory to prevent rebound ketoacidosis due to the short half-life of intravenous insulin.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru